AstraZeneca Unit Owes $130M In Chancery Scuttled-Drug Suit
The Delaware Chancery Court awarded $130 million to former shareholders of biopharmaceutical company Syntimmune in their breach of contract fight against AstraZeneca PLC unit Alexion Pharmaceuticals Inc., finding that Alexion failed...To view the full article, register now.
Already a subscriber? Click here to view full article